Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study

被引:33
作者
Loutradis, Charalampos [1 ]
Tolika, Panagiota [2 ]
Skodra, Alexandra [2 ]
Avdelidou, Afroditi [2 ]
Sarafidis, Pantelis A. [1 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Nephrol, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece
[2] Gen Hosp Grevena, Hemodialysis Unit, Grevena, Greece
关键词
Hyperkalemia; Diabetes; Chronic kidney disease; Angiotensin-converting enzyme inhibitors; GLOMERULAR-FILTRATION-RATE; POTASSIUM; HYPERTENSION; PREDICTORS; MELLITUS; BLOCKADE;
D O I
10.1159/000442393
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Hyperkalemia is a potentially life-threatening disorder, usually complicating chronic kidney disease (CKD). Factors superimposed to reduced renal function are further elevating hyperkalemia risk, but their contribution is not fully elucidated. This study aimed to compare the prevalence of hyperkalemia in diabetic and non-diabetic patients with CKD. Methods: This is a nested case-control study of 180 type-2 diabetic and 180 non-diabetic patients with CKD followed in a Nephrology outpatient clinic, matched for gender, age and estimated glomerular filtration rate. Type-1 diabetes or end-stage renal disease patients were excluded. Prevalence of hyperkalemia was defined as potassium >5 mEq/l or use of sodium polystyrene sulfonate, and further by potassium >5, >= 5.2 and >= 5.5 mEq/1. It was calculated in both groups in whole and CKD stages separately. Univariate and multivariate logistic regression analysis were conducted to identify factors associated with hyperkalemia. Results: The prevalence of hyperkalemia was higher in diabetic CKD patients (27.2 vs. 20%, p = 0.107) and remained around 30% higher with all secondary definitions used, but never reached statistical significance. In Stage 2, no difference was noted (8.7 vs. 17.4%, p = 0.665); in Stage 3, it was significantly higher in diabetics (28.6 vs. 17.5%, p = 0.036); and in Stage 4, it was equally high in both groups (35.5 vs. 32.3%, p = 0.788). In multivariate analysis, Stage 4 CKD (OR 4.535, 95% CI 1.561-13.173), use of angiotensin-converting enzyme inhibitors (ACEls; OR 2.228, 95% CI 1.254-3.958) and smoking (OR 2.254, 95% CI 1.218-4.171) were independently associated with hyperkalemia. Conclusions: Diabetes mellitus was found to elevate the prevalence of hyperkalemia only in CKD Stage 3 patients (moderately impaired renal function). Advanced CKD at Stage 4 and ACEIs are major determinants of hyperkalemia occurrence. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:351 / 360
页数:10
相关论文
共 28 条
  • [1] Use of Aldosterone Antagonists in Heart Failure
    Albert, Nancy M.
    Yancy, Clyde W.
    Liang, Li
    Zhao, Xin
    Hernandez, Adrian F.
    Peterson, Eric D.
    Cannon, Christopher P.
    Fonarow, Gregg C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (15): : 1658 - 1665
  • [2] Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases
    Amir, Omalhassan
    Hassan, Yahaya
    Sarriff, Azmi
    Awaisu, Ahmed
    Aziz, Noorizan Abd
    Ismail, Omar
    [J]. PHARMACY WORLD & SCIENCE, 2009, 31 (03): : 387 - 393
  • [3] [Anonymous], 2010, DIABETES CARE, DOI DOI 10.2337/dc10-s062
  • [4] Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease The AMETHYST-DN Randomized Clinical Trial
    Bakris, George L.
    Pitt, Bertram
    Weir, Matthew R.
    Freeman, Mason W.
    Mayo, Martha R.
    Garza, Dahlia
    Stasiv, Yuri
    Zawadzki, Rezi
    Berman, Lance
    Bushinsky, David A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02): : 151 - 161
  • [5] ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
    Bakris, GL
    Siomos, M
    Richardson, D
    Janssen, I
    Bolton, WK
    Hebert, L
    Agarwal, R
    Catanzaro, D
    [J]. KIDNEY INTERNATIONAL, 2000, 58 (05) : 2084 - 2092
  • [6] Metabolic Complications in Elderly Adults with Chronic Kidney Disease
    Drawz, Paul E.
    Babineau, Denise C.
    Rahman, Mahboob
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (02) : 310 - 315
  • [7] eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population
    Drion, I.
    Joosten, H.
    Dikkeschei, L. D.
    Groenier, K. H.
    Bilo, H. J. G.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 (07) : 722 - 727
  • [8] The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
    Einhorn, Lisa M.
    Zhan, Min
    Hsu, Van Doren
    Walker, Lori D.
    Moen, Maureen F.
    Seliger, Stephen L.
    Weir, Matthew R.
    Fink, Jeffrey C.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (12) : 1156 - 1162
  • [9] CIGARETTE-SMOKING AND THE ADRENERGIC NERVOUS-SYSTEM
    GRASSI, G
    SERAVALLE, G
    CALHOUN, DA
    BOLLA, G
    MANCIA, G
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1992, 14 (1-2) : 251 - 260
  • [10] Association of Hypo- and Hyperkalemia with Disease Progression and Mortality in Males with Chronic Kidney Disease: The Role of Race
    Hayes, John
    Kalantar-Zadeh, Kamyar
    Lu, Jun L.
    Turban, Sharon
    Anderson, John E.
    Kovesdy, Csaba P.
    [J]. NEPHRON CLINICAL PRACTICE, 2012, 120 (01): : C8 - C16